Serum TSH values and risk of vertebral fractures in euthyroid post-menopausal women with low bone mineral density

Bone

Volumn 46, Issue 3, 2010, Pages 747-751

  Mazziotti, Gherardo ^a,b   Porcelli, Teresa ^a   Patelli, Ilaria ^a   Vescovi, Pier Paolo ^b   Giustina, Andrea ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b CARLO POMA HOSPITAL   (Italy)

Author keywords

Bone mineral density; Fractures; Post menopausal osteoporosis; Thyroid; TSH

Indexed keywords

ADULT; AGE; AGED; ARTICLE; BODY MASS; CONTROLLED STUDY; DISEASE SEVERITY; EUTHYROIDISM; FEMALE; FRAGILITY FRACTURE; HUMAN; MAJOR CLINICAL STUDY; OSTEOPENIA; POSTMENOPAUSE OSTEOPOROSIS; PREVALENCE; THYROTROPIN BLOOD LEVEL; THYROXINE BLOOD LEVEL; VERTEBRA FRACTURE; BLOOD; BONE DENSITY; COHORT ANALYSIS; COMPARATIVE STUDY; EUTHYROID SICK SYNDROME; LUMBAR VERTEBRA; MIDDLE AGED; PHYSIOLOGY; POSTMENOPAUSE; RADIOGRAPHY; SPINE FRACTURE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BONE DENSITY; COHORT STUDIES; EUTHYROID SICK SYNDROMES; FEMALE; HUMANS; LUMBAR VERTEBRAE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; POSTMENOPAUSE; SPINAL FRACTURES; THYROTROPIN;

BIOLOGICAL MARKER; THYROTROPIN;

EID: 77649179121     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2009.10.031     Document Type: Article

References (34)

1. Sun L., Davies T.F., Blair H.C., Abe E., Zaidi M. TSH and bone loss. Ann. N. Y. Acad. Sci. 2006, 1068:309-318.
2. Abe E., Marians R.C., Yu W., Wu X.B., Ando T., Li Y., et al. TSH is a negative regulator of skeletal remodeling. Cell 2003, 115:151-162.
3. Sun L., Vukicevic S., Baliram R., Yang G., Sendak R., McPherson J., et al. Intermittent recombinant TSH injections prevent ovariectomy-induced bone loss. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:4289-4294.
4. Morimura T., Tsunekawa K., Kasahara T., Seki K., Ogiwara T., Mori M., et al. Expression of type 2 iodothyronine deiodinase in human osteoblast is stimulated by thyrotropin. Endocrinology 2005, 146:2077-2084.
5. Mazziotti G., Sorvillo F., Piscopo M., Cioffi M., Pilla P., Biondi B., et al. Recombinant human TSH modulates in vivo C-telopeptides of type-1 collagen and bone alkaline phosphatase, but not osteoprotegerin production in postmenopausal women monitored for differentiated thyroid carcinoma. J. Bone Miner. Res. 2005, 20:480-486.
6. Giusti M., Cecoli F., Ghiara C., Rubinacci A., Villa I., Cavallero D., et al. Recombinant human thyroid stimulating hormone does not acutely change serum osteoprotegerin and soluble receptor activator of nuclear factor-kappaBeta ligand in patients under evaluation for differentiated thyroid carcinoma. Hormones 2007, 6:304-313.
7. Martini G., Gennari L., De Paola V., Pilli T., Salvadori S., Merlotti D., et al. The effects of recombinant TSH on bone turnover markers and serum osteoprotegerin and RANKL levels. Thyroid 2008, 18:455-460.
8. Kim D.J., Khang Y.H., Koh J.M., Shong Y.K., Kim G.S. Low normal TSH levels are associated with low bone mineral density in healthy postmenopausal women. Clin. Endocrinol. 2006, 64:86-90.
9. Morris M.S. The association between serum thyroid-stimulating hormone in its reference range and bone status in postmenopausal American women. Bone 2007, 40:1128-1134.
10. Bauer D.C., Ettinger B., Nevitt M.C., Stone K.L. Study of Osteoporotic Fractures Research Group. Risk for fracture in women with low serum levels of thyroid-stimulating hormone. Ann. Intern. Med. 2001, 134:561-568.
11. Bassett J.H., Williams G.R. Critical role of the hypothalamic-pituitary-thyroid axis in bone. Bone 2008, 43:418-426.
12. Heemstra K.A., Hamdy N.A., Romijn J.A., Smit J.W. The effects of thyrotropin-suppressive therapy on bone metabolism in patients with well-differentiated thyroid carcinoma. Thyroid 2006, 16:583-591.
13. Biondi B., Cooper D.S. The clinical significance of subclinical thyroid dysfunction. Endocr. Rev. 2008, 29:76-131.
14. Kanis J.A., McCloskey E.V., Johansson H., Strom O., Borgstrom F., Oden A. National Osteoporosis Guideline Group. Case finding for the management of osteoporosis with FRAX-assessment and intervention thresholds for the UK. Osteoporos. Int. 2008, 19:1395-1408.
15. Kanis J.A., Burlet N., Cooper C., Delmas P.D., Reginster J.Y., Borgstrom F., et al. European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos. Int. 2008, 19:399-428.
16. Genant H.K., Jergas M., Palermo L., Nevitt M., Valentin R.S., Black D., et al. Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in the osteoporosis. The Study of Osteoporotic Fractures Research Group. J. Bone Min. Res. 1996, 11:984-996.
17. Jalava T., Sarna S., Pylkkänen L., Mawer B., Kanis J.A., Selby P., et al. Association between vertebral fracture and increased mortality in osteoporotic patients. J. Bone Min. Res. 2003, 18:1254-1260.
18. Lindsay R., Pack S., Li Z. Longitudinal progression of fracture prevalence through a population of postmenopausal women with osteoporosis. Osteoporos. Int. 2005, 16:306-312.
19. Grigoryan M., Guermazi A., Roemer F.W., Delmas P.D., Genant H.K. Recognizing and reporting osteoporotic vertebral fractures. Eur. Spine J. 2003, 12:S104-112.
20. Angeli A., Guglielmi G., Dovio A., Capelli G., de Feo D., Giannini S., et al. High prevalence of asymptomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid therapy: a cross-sectional outpatient study. Bone 2006, 39:253-259.
21. Johnell O., Kanis J.A., Oden A., Johansson H., De Laet C., Delmas P., et al. Predictive value of BMD for hip and other fractures. J. Bone Miner. Res. 2005, 20:1185-1194.
22. Bauer D.C. Bone: does TSH concentration influence skeletal health?. Nat. Rev. Endocrinol. 2009, 5:245-246.
23. Grimnes G., Emaus N., Joakimsen R.M., Figenschau Y., Jorde R. The relationship between serum TSH and bone mineral density in men and postmenopausal women: the Tromsø study. Thyroid 2008, 18:1147-1155.
24. Asvold B.O., Vatten L.J., Nilsen T.I., Bjøro T. The association between TSH within the reference range and serum lipid concentrations in a population-based study. The HUNT Study. Eur. J. Endocrinol. 2007, 156:181-186.
25. Knudsen N., Laurberg P., Rasmussen L.B., Bülow I., Perrild H., Ovesen L., et al. Small differences in thyroid function may be important for body mass index and the occurrence of obesity in the population. J. Clin. Endocrinol. Metab. 2005, 90:4019-4024.
26. De Laet C., Kanis J.A., Odén A., Johanson H., Johnell O., Delmas P., et al. Body mass index as a predictor of fracture risk: a meta-analysis. Osteoporos. Int. 2005, 16:1330-1338.
27. Mazziotti G., Bianchi A., Bonadonna S., Nuzzo M., Cimino V., Fusco A., et al. Increased prevalence of radiological spinal deformities in adult patients with GH deficiency: influence of GH replacement therapy. J. Bone Miner. Res. 2006, 21:520-528.
28. Bonadonna S., Mazziotti G., Nuzzo M., Bianchi A., Fusco A., De Marinis L., et al. Increased prevalence of radiological spinal deformities in active acromegaly: a cross-sectional study in postmenopausal women. J. Bone Miner. Res. 2005, 20:1837-1844.
29. Mazziotti G., Angeli A., Bilezikian J.P., Canalis E., Giustina A. Glucocorticoid-induced osteoporosis: an update. Trends Endocrinol. Metab. 2006, 7:144-149.
30. Canalis E., Mazziotti G., Giustina A., Bilezikian J.P. Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos. Int. 2007, 18:1319-1328.
31. Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes-a meta-analysis. Osteoporos. Int. 2007, 18:427-444.
32. Dayan C.M., Saravanan P., Bayly G. Whose normal thyroid function is better-yours or mine?. Lancet 2002, 360:353.
33. Giustina A., Mazziotti G., Canalis E. Growth hormone, insulin-like growth factors, and the skeleton. Endocr. Rev. 2008, 29:535-559.
34. Parle J.V., Franklyn J.A., Cross K.W., Jones S.R., Sheppard M.C. Thyroxine prescription in the community: serum thyroid stimulating hormone level assays as an indicator of undertreatment or overtreatment. Br. J. Gen. Pract. 1993, 43:107-109.